China’s First mRNA Covid Shot Triggers 80%–95% Immune Response

China’s first home-grown Covid-19 vaccine using mRNA technology can trigger an immune response in as many as 95% of recipients with no severe adverse reaction reported, according to data from the first stage of clinical trials.

The vaccine, known as ARCoV, is being jointly developed by Walvax Biotechnology Co., Suzhou Abogen Biosciences (300142.SZ) and the PLA Academy of Military Science.